

Cory Johannessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3649338/publications.pdf>

Version: 2024-02-01

23
papers

8,106
citations

471509

17
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

15694
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic identification of biomarker-driven drug combinations to overcome resistance. <i>Nature Chemical Biology</i> , 2022, 18, 615-624.	8.0	14
2	Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCI/BACH1/BRIP1. <i>Molecular Cancer Research</i> , 2021, 19, 1015-1025.	3.4	15
3	Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. <i>Nature Genetics</i> , 2021, 53, 1664-1672.	21.4	61
4	Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization. <i>Cell Systems</i> , 2020, 10, 52-65.e7.	6.2	10
5	Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 92-104.	8.2	30
6	CloneSifter: enrichment of rare clones from heterogeneous cell populations. <i>BMC Biology</i> , 2020, 18, 177.	3.8	12
7	Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. <i>Clinical Cancer Research</i> , 2020, 26, 4995-5006.	7.0	14
8	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2281-2293.	3.4	29
9	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	12.8	37
10	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , 2019, 569, 503-508.	27.8	2,149
11	A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. <i>Cancer Research</i> , 2019, 79, 2352-2366.	0.9	34
12	Mutational processes shape the landscape of TP53 mutations in human cancer. <i>Nature Genetics</i> , 2018, 50, 1381-1387.	21.4	334
13	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	16.8	181
14	Progress towards precision functional genomics in cancer. <i>Current Opinion in Systems Biology</i> , 2017, 2, 74-83.	2.6	7
15	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	12.8	584
16	Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants. <i>Cell Reports</i> , 2016, 17, 1171-1183.	6.4	119
17	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. <i>Cancer Cell</i> , 2015, 27, 397-408.	16.8	150
18	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. <i>Cancer Discovery</i> , 2014, 4, 94-109.	9.4	782

#	ARTICLE	IF	CITATIONS
19	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	9.4	448
20	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. <i>Nature</i> , 2013, 504, 138-142.	27.8	401
21	A public genome-scale lentiviral expression library of human ORFs. <i>Nature Methods</i> , 2011, 8, 659-661.	19.0	477
22	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. <i>Journal of Clinical Oncology</i> , 2011, 29, 3085-3096.	1.6	890
23	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010, 468, 968-972.	27.8	1,325